Filing Details
- Accession Number:
- 0001209191-18-007206
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-02 19:26:46
- Reporting Period:
- 2018-01-31
- Accepted Time:
- 2018-02-02 19:26:46
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1594864 | Juno Therapeutics Inc. | JUNO | Biological Products, (No Disgnostic Substances) (2836) | 463656275 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1656998 | Robert Azelby | C/O 400 Dexter Avenue North Suite 1200 Seattle WA 98109 | Evp & Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-01-31 | 25,639 | $0.00 | 96,471 | No | 4 | A | Direct | |
Common Stock | Acquisiton | 2018-02-01 | 4,167 | $51.76 | 100,638 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-02-01 | 4,167 | $85.78 | 96,471 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2018-02-01 | 4,167 | $0.00 | 4,167 | $51.76 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
93,294 | 2025-10-31 | No | 4 | M | Direct |
Footnotes
- Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of January 31, 2018.
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.
- 25% of the shares subject to the option vested and became exercisable on November 1, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.